7790±Ø·¢¼¯ÍÅ

7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ 7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
¹ÉƱ´úÂëΪ£¨300404£©½¨ÉèÓÚ2002Ä꣬£¬ £¬£¬£¬£¬£¬2015ÄêÔÚÉîÛÚ´´Òµ°åÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»¼ÒΪº£ÄÚÍâÒ½Ò©ÆóÒµÌṩҩƷ¡¢±£½¡Æ·¡¢Ò½ÁÆÆ÷еÑз¢ÓëÉú²úÈ«Á÷³Ì¡°Ò»Õ¾Ê½¡±Íâ°ü·þÎñ(CRO)µÄÐ͸ßÐÂÊÖÒÕÆóÒµ£¬£¬ £¬£¬£¬£¬£¬Í¬Ò²ÌṩҩƷÉÏÊÐÔÊÐí³ÖÓÐÈË(MAH)·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
¹ÉƱ´úÂëΪ£¨300404£©½¨ÉèÓÚ2002Ä꣬£¬ £¬£¬£¬£¬£¬2015ÄêÔÚÉîÛÚ´´Òµ°åÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»¼ÒΪº£ÄÚÍâÒ½Ò©ÆóÒµÌṩҩƷ¡¢±£½¡Æ·¡¢Ò½ÁÆÆ÷еÑз¢ÓëÉú²úÈ«Á÷³Ì¡°Ò»Õ¾Ê½¡±Íâ°ü·þÎñ(CRO)µÄÐ͸ßÐÂÊÖÒÕÆóÒµ£¬£¬ £¬£¬£¬£¬£¬Í¬Ò²ÌṩҩƷÉÏÊÐÔÊÐí³ÖÓÐÈË(MAH)·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
¹ÉƱ´úÂëΪ£¨300404£©½¨ÉèÓÚ2002Ä꣬£¬ £¬£¬£¬£¬£¬2015ÄêÔÚÉîÛÚ´´Òµ°åÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»¼ÒΪº£ÄÚÍâÒ½Ò©ÆóÒµÌṩҩƷ¡¢±£½¡Æ·¡¢Ò½ÁÆÆ÷еÑз¢ÓëÉú²úÈ«Á÷³Ì¡°Ò»Õ¾Ê½¡±Íâ°ü·þÎñ(CRO)µÄÐ͸ßÐÂÊÖÒÕÆóÒµ£¬£¬ £¬£¬£¬£¬£¬Í¬Ò²ÌṩҩƷÉÏÊÐÔÊÐí³ÖÓÐÈË(MAH)·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
¹ÉƱ´úÂëΪ£¨300404£©½¨ÉèÓÚ2002Ä꣬£¬ £¬£¬£¬£¬£¬2015ÄêÔÚÉîÛÚ´´Òµ°åÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»¼ÒΪº£ÄÚÍâÒ½Ò©ÆóÒµÌṩҩƷ¡¢±£½¡Æ·¡¢Ò½ÁÆÆ÷еÑз¢ÓëÉú²úÈ«Á÷³Ì¡°Ò»Õ¾Ê½¡±Íâ°ü·þÎñ(CRO)µÄÐ͸ßÐÂÊÖÒÕÆóÒµ£¬£¬ £¬£¬£¬£¬£¬Í¬Ò²ÌṩҩƷÉÏÊÐÔÊÐí³ÖÓÐÈË(MAH)·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
¹ÉƱ´úÂëΪ£¨300404£©½¨ÉèÓÚ2002Ä꣬£¬ £¬£¬£¬£¬£¬2015ÄêÔÚÉîÛÚ´´Òµ°åÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»¼ÒΪº£ÄÚÍâÒ½Ò©ÆóÒµÌṩҩƷ¡¢±£½¡Æ·¡¢Ò½ÁÆÆ÷еÑз¢ÓëÉú²úÈ«Á÷³Ì¡°Ò»Õ¾Ê½¡±Íâ°ü·þÎñ(CRO)µÄÐ͸ßÐÂÊÖÒÕÆóÒµ£¬£¬ £¬£¬£¬£¬£¬Í¬Ò²ÌṩҩƷÉÏÊÐÔÊÐí³ÖÓÐÈË(MAH)·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
¹ÉƱ´úÂëΪ£¨300404£©½¨ÉèÓÚ2002Ä꣬£¬ £¬£¬£¬£¬£¬2015ÄêÔÚÉîÛÚ´´Òµ°åÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»¼ÒΪº£ÄÚÍâÒ½Ò©ÆóÒµÌṩҩƷ¡¢±£½¡Æ·¡¢Ò½ÁÆÆ÷еÑз¢ÓëÉú²úÈ«Á÷³Ì¡°Ò»Õ¾Ê½¡±Íâ°ü·þÎñ(CRO)µÄÐ͸ßÐÂÊÖÒÕÆóÒµ£¬£¬ £¬£¬£¬£¬£¬Í¬Ò²ÌṩҩƷÉÏÊÐÔÊÐí³ÖÓÐÈË(MAH)·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
¹ÉƱ´úÂëΪ£¨300404£©½¨ÉèÓÚ2002Ä꣬£¬ £¬£¬£¬£¬£¬2015ÄêÔÚÉîÛÚ´´Òµ°åÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»¼ÒΪº£ÄÚÍâÒ½Ò©ÆóÒµÌṩҩƷ¡¢±£½¡Æ·¡¢Ò½ÁÆÆ÷еÑз¢ÓëÉú²úÈ«Á÷³Ì¡°Ò»Õ¾Ê½¡±Íâ°ü·þÎñ(CRO)µÄÐ͸ßÐÂÊÖÒÕÆóÒµ£¬£¬ £¬£¬£¬£¬£¬Í¬Ò²ÌṩҩƷÉÏÊÐÔÊÐí³ÖÓÐÈË(MAH)·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢¼¼
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢¼¼
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢¼¼
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢¼¼
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢¼¼
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢¼¼
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢¼¼
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢¼¼
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢ÊÖÒÕЧ¹ûת»¯µÈ£¬£¬ £¬£¬£¬£¬£¬Í¬Ê±ÌṩҩƷÏòÃÀ¹ú¡¢Å·ÃË×¢²áÉ걨·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢ÊÖÒÕЧ¹ûת»¯µÈ£¬£¬ £¬£¬£¬£¬£¬Í¬Ê±ÌṩҩƷÏòÃÀ¹ú¡¢Å·ÃË×¢²áÉ걨·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢ÊÖÒÕЧ¹ûת»¯µÈ£¬£¬ £¬£¬£¬£¬£¬Í¬Ê±ÌṩҩƷÏòÃÀ¹ú¡¢Å·ÃË×¢²áÉ걨·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢ÊÖÒÕЧ¹ûת»¯µÈ£¬£¬ £¬£¬£¬£¬£¬Í¬Ê±ÌṩҩƷÏòÃÀ¹ú¡¢Å·ÃË×¢²áÉ걨·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢ÊÖÒÕЧ¹ûת»¯µÈ£¬£¬ £¬£¬£¬£¬£¬Í¬Ê±ÌṩҩƷÏòÃÀ¹ú¡¢Å·ÃË×¢²áÉ걨·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢ÊÖÒÕЧ¹ûת»¯µÈ£¬£¬ £¬£¬£¬£¬£¬Í¬Ê±ÌṩҩƷÏòÃÀ¹ú¡¢Å·ÃË×¢²áÉ걨·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
Ò©Æ·Ñз¢¡°Ò»Õ¾Ê½¡±·þÎñ°üÀ¨£ºÐÂÒ©Á¢ÏîÑо¿ºÍ»îÐÔɸѡ¡¢Ò©Ñ§Ñо¿(º¬ÖÐÊÔÉú²ú)¡¢Ò©Àí¶¾ÀíÑо¿¡¢ÁÙ´²ÓÃÒ©ÓëÄ£Äâ¼ÁµÄÉú²ú¡¢ÁÙ´²ÊÔÑé¡¢ÁÙ´²Êý¾Ý¹ÜÀíºÍͳ¼ÆÆÊÎö¡¢ÉÏÊкóÔÙÆÀ¼Û¡¢ÊÖÒÕЧ¹ûת»¯µÈ£¬£¬ £¬£¬£¬£¬£¬Í¬Ê±ÌṩҩƷÏòÃÀ¹ú¡¢Å·ÃË×¢²áÉ걨·þÎñ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
¹«Ë¾ÓµÓнü3000ƽÃ×µÄÏÖ´ú»¯°ì¹«³¡ºÏ£¬£¬ £¬£¬£¬£¬£¬»ã¾ÛÁ˳¬1000ÃûÂÄÀú¸»ºñ£¬£¬ £¬£¬£¬£¬£¬Ñ§Ê¶Ô¨²©£¬£¬ £¬£¬£¬£¬£¬Í·ÄÔѸËÙµÄÖи߼¶Ò½Ò©Ñо¿È˲źÍ×¢²á¹æÔòר¼Ò¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ
7790±Ø·¢¼¯ÍÅҽҩʼÖÕ¼á³Ö¡°ÖÒʵ¡¢ÊØÐÅ¡¢×¨Òµ¡¢È¨Íþ¡±µÄı»®ÀíÄ£¬ £¬£¬£¬£¬£¬×èÖ¹2020Ä꣬£¬ £¬£¬£¬£¬£¬¹«Ë¾ÀÛ¼ÆÎª¿Í»§ÌṩÁÙ´²Ñо¿·þÎñ800ÓàÏ£¬ £¬£¬£¬£¬£¬»ù±¾º­¸ÇÁËÒ©ÎïÖÎÁƵĸ÷¸öרҵÁìÓò;ÀÛ¼ÆÍê³ÉÁÙ´²Ç°Ñо¿·þÎñ500¶àÏî¡£¡£¡£¡£¡£¡£¾­Óɽü¶þÊ®ÄêµÄÉú³¤£¬£¬ £¬£¬£¬£¬£¬7790±Ø·¢¼¯ÍÅÒ½Ò©ÔÚÊÖÒÕʵÁ¦¡¢·þÎñÖÊÁ¿¡¢·þÎñ¹æÄ£¡¢ÓªÒµÊÕÈë¡¢ÍŶӽ¨ÉèµÈ·½Ãæ¶¼ÒÑõÒÉíÎÒ¹úCRO¹«Ë¾µÄÁìÏÈλÖ㬣¬ £¬£¬£¬£¬£¬³ÉΪÎÒ¹ú±¾ÍÁ´óÐÍCRO¹«Ë¾µÄÁúÍ·ÆóÒµ¡£¡£¡£¡£¡£¡£
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
ÐÐÒµ¶¯Ì¬
ÅÌ»õ£º2020ÄêFDA¹²Åú×¼53¿îÐÂÒ©ÉÏÊУ¬£¬ £¬£¬£¬£¬£¬Ð¡·Ö×ÓÒ©ÎïÕ¼±È³¬70%£¬£¬ £¬£¬£¬£¬£¬³É×î´óÓ®¼Ò£¡
×÷Õߣº¹ãÖÝ7790±Ø·¢¼¯ÍÅÒ½Ò© ʱ¼ä£º2021-01-04 ȪԴ£º¹ãÖÝ7790±Ø·¢¼¯ÍÅÒ½Ò©

2020Ä꣬£¬ £¬£¬£¬£¬£¬FDA¹²Åú×¼53¿îÐÂÒ©£¬£¬ £¬£¬£¬£¬£¬Åú×¼ÐÂÒ©ÊýÄ¿ÔÚ½ü10ÄêÀïλ¾ÓµÚ¶þ¡£¡£¡£¡£¡£¡£


ËäÈ»£¬£¬ £¬£¬£¬£¬£¬ÒßÇé¶Ô¸÷¼Ò¹«Ë¾µÄÒ©Î↑·¢ÍýÏ뱬·¢½Ï´óÓ°Ï죬£¬ £¬£¬£¬£¬£¬Ò²¶Ô¸÷¹úÕþ¸®î¿Ïµ»ú¹¹µÄÒ»Ñùƽ³£ÔËÐÐÔì³ÉÁ˹¥»÷£¬£¬ £¬£¬£¬£¬£¬¿ÉÊÇFDAÔÚ2020ÄêµÄÒ©Æ·ÉóÅúËÙÂÊË¿ºÁûÓзŻº£¬£¬ £¬£¬£¬£¬£¬Ð¡·Ö×ÓÐÂÒ©¸üÊÇÒÔ38¸öÅú×¼Êý£¬£¬ £¬£¬£¬£¬£¬³ÉΪÁË¡°»ñÅúй󡱡£¡£¡£¡£¡£¡£

´Ó¼²²¡ÁìÓòÀ´¿´£¬£¬ £¬£¬£¬£¬£¬2020ÄêFDAÅú×¼µÄÐÂÒ©ÈÔÒÔÖ×ÁöÒ©¾Ó¶à£¬£¬ £¬£¬£¬£¬£¬Õ¼±È34%£¨18/53£©£¬£¬ £¬£¬£¬£¬£¬ÆäËûÕ¼½ÏÁ¿¸ßµÄ¼²²¡ÁìÓò»¹°üÀ¨Éñ¾­£¨15%£¬£¬ £¬£¬£¬£¬£¬8/53£©¡¢ÄÚÉøÍ¸´úл£¨9%£¬£¬ £¬£¬£¬£¬£¬5/53£©¡¢Õï¶ÏÊÔ¼Á£¨7%£¬£¬ £¬£¬£¬£¬£¬4/53£©¡¢Ñ¬È¾ÐÔ¼²²¡£¡£¡£¡£¡£¡£¨7%£¬£¬ £¬£¬£¬£¬£¬4/53£©¡£¡£¡£¡£¡£¡£


´ÓÒ©Îï¼ÁÐÍÀ´¿´£¬£¬ £¬£¬£¬£¬£¬2020ÄêFDAÅú×¼µÄÐÂÒ©ÖÐ×¢Éä¼Á×î¶à£¬£¬ £¬£¬£¬£¬£¬Õ¼±È50%£¨26/53£©£¬£¬ £¬£¬£¬£¬£¬Æä´ÎÊÇͨË׿ڷþƬ¼ÁºÍ½ºÄÒ¼Á¡£¡£¡£¡£¡£¡£


´ÓÉóÆÀ·½·¨ÉÏ¿´£¬£¬ £¬£¬£¬£¬£¬½ñÄê¹²ÓÐ26¸öÐÂÒ©ÊÇÒÔ¡°ÓÅÏÈÉóÆÀ¡±µÄ·½·¨»ñµÃFDAÅú×¼ÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÆäÖаüÀ¨23¸öС·Ö×ÓʵÌåºÍ3¸öÐÂÉúÎïÖÆÆ·¡£¡£¡£¡£¡£¡£ÓÐ31¸öÆ·ÖÖ±»FDAÊÚÓè¡°¹Â¶ùÒ©¡±×ʸñ£¬£¬ £¬£¬£¬£¬£¬Õ¼ËùÓлñÅúÐÂÒ©µÄ58%¡£¡£¡£¡£¡£¡£


2020ÄêFDA»ñÅúµÄÐÂÒ©ÖУ¬£¬ £¬£¬£¬£¬£¬ÓÐ9¿îÊôÓÚFirst-in-classÒ©Î£¬ £¬£¬£¬£¬£¬ÏêϸƷÖÖÈçÏ£º



ÖµµÃÒ»ÌáµÄÊÇ£¬£¬ £¬£¬£¬£¬£¬FDA»ñÅúÉÏÊеÄ53¿îÐÂÒ©ÖÐÓÐ38¸öÊÇС·Ö×ÓÒ©Îï½á¹¹£¬£¬ £¬£¬£¬£¬£¬Õ¼±È³¬70%¡£¡£¡£¡£¡£¡£


1£¬£¬ £¬£¬£¬£¬£¬Avapritinib (BLU-285) °¢·¥ÆÕÀûÄá

Avapritinib (BLU-285)ÊÇÒ»ÖÖС·Ö×Ó¼¤Ã¸ÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬¿ÉÓÐÓÃÒÖÖÆPDGFR¦Á D842VÍ»±äÌåµÄ»îÐÔ¡¢ÔÚϸ°ûÅä¾°ÏÂÒÖÖÆPDGFR¦Á D842V×ÔÎÒÁ×Ëữ£¨IC50=30 nM£© £»£»£»£»£»£»£» £»Í¬Ê±Ò²ÊÇKITÍ»±ä£¨KIT D816V£©µÄÒÖÖÆ¼Á£¨IC50=0.5 nM£©¡£¡£¡£¡£¡£¡£



2£¬£¬ £¬£¬£¬£¬£¬Tazemetostat (EPZ-6438)

Tazverik(tazemetostat)  (EPZ-6438) ÊÇ×éÂѰ×Àµ°±Ëá¼×»ù×ªÒÆÃ¸£¨Histone-Lysine N-methyltransferase£©EZH2µÄÒÖÖÆ¼Á¡£¡£¡£¡£¡£¡£



3£¬£¬ £¬£¬£¬£¬£¬Pizensy(ÈéÌÇ´¼)

PizensyÊÇÒ»ÖÖ¿Ú·þµÄÈé¹ûÌÇÀàËÆÎï¡£¡£¡£¡£¡£¡£ËüÊÇÒ»ÖÖÉøÍ¸ÐÔкҩ£¨osmotic laxitaive£©£¬£¬ £¬£¬£¬£¬£¬¿ÉÔö½øË®·ÖÁ÷È볦µÀ£¬£¬ £¬£¬£¬£¬£¬½ø¶øÔڽ᳦ÄÚµÖ´ïͨ±ã×÷Óᣡ£¡£¡£¡£¡£



4£¬£¬ £¬£¬£¬£¬£¬Nexletol (bempedoic acid)

bempedoic acidÓÉÃÀ¹úEsperion Therapeutic ¹«Ë¾Ñз¢£¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»ÖÖÖÎÁÆÑªÖ¬Òì³£¼°½µµÍÆäËûÐÄѪ¹Ü¼²²¡Î£º¦µÄÐÂÐÍС·Ö×Ó»¯ºÏÎï¡£¡£¡£¡£¡£¡£



ºÏ³Éõè¾¶ÈçÏ£º



5£¬£¬ £¬£¬£¬£¬£¬Barhemsys(°±»Ç±ØÀû)

°±»Ç±ØÀûÊÇÒ»¸ö¶à°Í°·D2ºÍD3ÊÜÌå×è¶Ï¼Á£¬£¬ £¬£¬£¬£¬£¬ÉÏÊÀ¼Í80ÄêÔÂ×îÏÈÓ¦ÓÃÓÚ¾«ÉñÆÆËéÖ¢ÖÎÁÆ¡£¡£¡£¡£¡£¡£

6£¬£¬ £¬£¬£¬£¬£¬Nurtec ODT£¨rimegepant£©

Biohaven¹«Ë¾µÄ¿Ú·þCGRPÒÖÖÆ¼Árimegepant£¬£¬ £¬£¬£¬£¬£¬ÓÃÓÚ³ÉÈËÆ«Í·Í´µÄ¼±ÐÔÖÎÁÆ¡£¡£¡£¡£¡£¡£



7£¬£¬ £¬£¬£¬£¬£¬Isturisa(osilodrostat)

3ÔÂ6ÈÕ£¬£¬ £¬£¬£¬£¬£¬FDAÅú×¼¿âÐÀ×ÛºÏÕ÷£¨Cushing syndrome£¬£¬ £¬£¬£¬£¬£¬CS£©Ò»ÏßÓÃÒ©OsilodrostatÉÏÊУ¬£¬ £¬£¬£¬£¬£¬ÉÌÆ·Ãû£ºIsturisa£¬£¬ £¬£¬£¬£¬£¬»¼ÕßÎÞÂÛÊÇ·ñ½ÓÊÜÊܹý´¹ÌåÇгýÊÖÊõÖÎÁÆ£¬£¬ £¬£¬£¬£¬£¬¶¼¿ÉÓ¦ÓÃOsilodrostat×÷ΪÖÎÁÆÒ©Îï¡£¡£¡£¡£¡£¡£OsilodrostatÊÇFDAÅú×¼µÄÊ׸ö11-¦ÂôÇ»¯Ã¸ÒÖÖÆ£¬£¬ £¬£¬£¬£¬£¬¿ÉÖ±½Ó×è¶ÏÉöÉÏÏÙÆ¤ÖÊ´¼ºÏ³É¡£¡£¡£¡£¡£¡£



8£¬£¬ £¬£¬£¬£¬£¬Zeposia(ozanimod)

ozanimod£¨ÉÌÆ·ÃûZEPOSIA£©£¬£¬ £¬£¬£¬£¬£¬ÓÃÓÚ³ÉÈ˸´·¢ÐÔMS£¨RRMS£©»¼ÕßµÄÖÎÁÆ¡£¡£¡£¡£¡£¡£



9£¬£¬ £¬£¬£¬£¬£¬Selumetinib£¨Ë¾ÃÀÌæÄᣩ

Selumetinib £¨Ë¾ÃÀÌæÄᣩ£¨ARRY-142886 ; AZD6244£©ÊÇÒ»ÖÖMEK 1/2ÒÖÖÆ¼ÁºÍDZÔÚµÄÐÂÒ©£¬£¬ £¬£¬£¬£¬£¬ÓÉAlstraZenecaÓÚ2003Äê»ñµÃArray BioPharma Inc.µÄÔÊÐí¡£¡£¡£¡£¡£¡£°¢Ë¹Àû¿µºÍMSDÓÚ2017ÄêÇ©ÊðÁËselumetinibµÄÅäºÏ¿ª·¢ºÍÍŽáÉÌÒµ»¯Ð­Òé¡£¡£¡£¡£¡£¡£



10£¬£¬ £¬£¬£¬£¬£¬Tukysa(Tucatinib)

Tukysa£¨Tucatinib£©Í׿¨ÌæÄá /ͼ¿¨ÌæÄá (ONT-380)ÊÇÒ»ÖÖ¿Ú·þTKI(ÀÒ°±Ëἤø)ÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬¶ÔHER2¾ßÓи߶ÈÌØÒìÐÔ£¬£¬ £¬£¬£¬£¬£¬µ«¶ÔͬÊôÈË±íÆ¤Éú³¤Òò×ÓÊÜÌå¼Ò×åµÄEGFRûÓÐÏÔ×ÅÒÖÖÆ×÷Óᣡ£¡£¡£¡£¡£



11£¬£¬ £¬£¬£¬£¬£¬Pemigatinib £¨ÅÁÃ×¼ÓÌæÄᣩ

Pemigatinib£¨INCB054828£©ÊÇÒ»ÖÖ¿Ú·þÓÐÓõÄ£¬£¬ £¬£¬£¬£¬£¬Ñ¡ÔñÐÔFGFRÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬Ëü¶ÔFGFR1£¬£¬ £¬£¬£¬£¬£¬FGFR2£¬£¬ £¬£¬£¬£¬£¬FGFR3£¬£¬ £¬£¬£¬£¬£¬FGFR4µÄIC50Öµ»®·ÖΪ0.4 nM£¬£¬ £¬£¬£¬£¬£¬0.5 nM£¬£¬ £¬£¬£¬£¬£¬1.2 nMºÍ30 nM¡£¡£¡£¡£¡£¡£



12£¬£¬ £¬£¬£¬£¬£¬Ongentys(opicapone)





13£¬£¬ £¬£¬£¬£¬£¬INCB28060 (Capmatinib) ¿¨ÂíÌæÄá £»£»£»£»£»£»£» £»±½ÔúÃ×ÌØ

INCB28060ÊÇÒ»ÖÖÐÂÐÍ£¬£¬ £¬£¬£¬£¬£¬ ATP¾ºÕùÐÔµÄc-METÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬IC50Ϊ0.13 nM£¬£¬ £¬£¬£¬£¬£¬ÒÖÖÆRON¦Â£¬£¬ £¬£¬£¬£¬£¬ EGFRºÍHER-3»îÐÔ¡£¡£¡£¡£¡£¡£





14£¬£¬ £¬£¬£¬£¬£¬Selpercatinib (LOXO-292) Èû¶ûÅÁÌæÄá

Selpercatinib£¨LOXO-292£©ÊÇÒ»ÖÖÓÐÓõÄ£¬£¬ £¬£¬£¬£¬£¬ÌØÒìÐÔRETÒÖÖÆ¼Á¡£¡£¡£¡£¡£¡£





15£¬£¬ £¬£¬£¬£¬£¬Ripretinib ÈðÆÕÌæÄá

Ripretinib£¨DCC-2618£©ÊÇÒ»ÖÖ¾ßÓпڷþ»îÐԵ쬣¬ £¬£¬£¬£¬£¬Ñ¡ÔñÐÔµÄKITºÍPDGFR-alphaÒÖÖÆ¼Á¡£¡£¡£¡£¡£¡£




16£¬£¬ £¬£¬£¬£¬£¬ Cerianna (fluoroestradiol F18)


17£¬£¬ £¬£¬£¬£¬£¬Artesunate£¨ÇàÝïçúõ¥£©

ÇàÝïçúõ¥ÊÇÒ»Àà¿ØÖÆÅ±¼²Ö¢×´µÄ¿¹Å±Ò©¡£¡£¡£¡£¡£¡£



18£¬£¬ £¬£¬£¬£¬£¬Tauvid£¨flortaucipir F18£©

Tauvid£¨flortaucipir F18£©ÊǵÚÒ»ÖÖ»ñµÃFDAÅú×¼£¬£¬ £¬£¬£¬£¬£¬×ÊÖú¶Ô´óÄÔÖеÄtau²¡Àí¾ÙÐгÉÏñµÄÒ©Îï¡£¡£¡£¡£¡£¡£TauvidÊÇÒ»ÖÖ·ÅÉäÐÔÕï¶ÏÊÔ¼Á£¬£¬ £¬£¬£¬£¬£¬ÓÃÓÚÐèÒª½ÓÊܰ¢¶û´Äº£Ä¬²¡ÆÀ¹ÀµÄÈÏÖªÕϰ­³ÉÈË»¼Õß¡£¡£¡£¡£¡£¡£



19£¬£¬ £¬£¬£¬£¬£¬Lurbinectedin£¨Â¬±È¿ËÌæ¶¨£©

lurbinectedinÊÇPharmaMarÑз¢µÄº£ÇÊËØÑÜÉúÎ£¬ £¬£¬£¬£¬£¬ÎªÖ×ÁöÁ¢ÒìÒ©¡£¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬ £¬£¬£¬£¬£¬ÂÌÒ¶ÖÆÒ©ÓëPharmaMarÔÚ»ªºÏ×÷ÅäºÏ¿ª·¢¸ÃÒ©Îï¡£¡£¡£¡£¡£¡£



20£¬£¬ £¬£¬£¬£¬£¬Dojolvi£¨triheptanoin£©Èý¸ýËá¸ÊÓÍõ¥

Dojolvi£¨triheptanoin£©Èý¸ýËá¸ÊÓÍõ¥£¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»Öָߴ¿¶È¡¢È˹¤ºÏ³ÉµÄ7̼֬·¾Ëá¸ÊÓÍÈýõ¥£¬£¬ £¬£¬£¬£¬£¬ÔÚ¸ÊÓ͹ǼÜÉÏͨ¹ý¶à¸ö»¯Ñ§ºÏ³É°ì·¨Ìí¼ÓÁËÈý¸ö7̼֬·¾ËáÐγÉ¡£¡£¡£¡£¡£¡£×¨ÃÅΪLC-FAOD»¼ÕßÌṩÖÐÁ´¡¢ÆæÊý̼֬·¾Ëá×÷ΪÄÜÔ´ºÍ´úл²úÆ·Ìæ»»Æ·¡£¡£¡£¡£¡£¡£



21£¬£¬ £¬£¬£¬£¬£¬Fostemsavir(BMS-663068)

Fostemsavir (BMS-663068) ÊÇ BMS-626529 µÄÔ­Ò©£¬£¬ £¬£¬£¬£¬£¬ÄÜÍŽágp120£¬£¬ £¬£¬£¬£¬£¬ÒÖÖÆ HIV-1 Óëϸ°û CD4 ÊÜÌåµÄÍŽá¡£¡£¡£¡£¡£¡£



22£¬£¬ £¬£¬£¬£¬£¬Byfavo£¨Remimazolam£©ÈðÃ×ßòÂØ/À×Ã×ÂíßòÂØ

Byfavo£¨Remimazolam£©ÈðÃ×ßòÂØ/À×Ã×ÂíßòÂØ ÊÇÒ»ÖÖÆðЧºÍʧЧѸËٵľ²Âö×¢Éä±½¶þµª×¿£¨benzodiazepine£©Õò¾²¼Á¡£¡£¡£¡£¡£¡£¿£¿£¿ £¿£¿£¿£¿ÉÓÃÓÚÔÚʱ³¤²»Áè¼Ý30·ÖÖÓµÄÓд´Ò½ÁƳÌÐòÖУ¬£¬ £¬£¬£¬£¬£¬ÀýÈç½á³¦¾µ¼ì²éºÍÖ§Æø¹Ü¾µ¼ì²é¡£¡£¡£¡£¡£¡£

23£¬£¬ £¬£¬£¬£¬£¬Inqovi(cedazuridine+µØÎ÷Ëû±õ)

Inqovi£¨cedazuridine/decitabine[µØÎ÷Ëû±õ]£¬£¬ £¬£¬£¬£¬£¬¿Ú·þC-DEC£¬£¬ £¬£¬£¬£¬£¬ASTX727£©£¬£¬ £¬£¬£¬£¬£¬¸ÃÒ©ÓÃÓÚ¹ÇËèÔöÉúÒì³£×ÛºÏÖ¢£¨MDS£©ºÍÂýÐÔ¹ÇËèµ¥ºËϸ°û°×Ѫ²¡£¨CMML£©³ÉÈË»¼ÕßµÄÖÎÁÆ¡£¡£¡£¡£¡£¡£

24£¬£¬ £¬£¬£¬£¬£¬Xeglyze(Abametapir)

Xeglyze£¨Abametapir£©0.74£¥ Ï´»¤¼Á ÊÇÒ»ÖÖ½ðÊôÂѰ×øÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬½ðÊôÂѰ×øÊǶԳæÂÑ·¢ÓýºÍÈô³æºÍ³É³æÊ­×Ó´æ»î£¬£¬ £¬£¬£¬£¬£¬ÖÁ¹ØÖ÷ÒªµÄÐÄÀíÀú³ÌËù±ØÐèµÄø¡£¡£¡£¡£¡£¡£



25£¬£¬ £¬£¬£¬£¬£¬Nifurtimox (Synonyms: Ïõß»ÌæÄª)

Nifurtimox ÊÇÒ»ÖÖÓÃÓÚ×¶³æ²¡ (Trypanosoma cruzi) µÄ¿¹³æ¼Á¡£¡£¡£¡£¡£¡£Nifurtimox ÓÐDZÁ¦ÓÃÓÚÉñ¾­Ä¸Ï¸°ûÁöϸ°ûµÄÑо¿¡£¡£¡£¡£¡£¡£Nifurtimox Ó°ÏìÈéËáÍÑÇâø (LDH) »îÐÔ¡£¡£¡£¡£¡£¡£



26£¬£¬ £¬£¬£¬£¬£¬Olinvyk£¨oliceridine£©

OlinvykµÄ»îÐÔÒ©ÎïÒòËØÎªoliceridine£¬£¬ £¬£¬£¬£¬£¬ÕâÊÇÒ»ÖÖÊ×´´µÄ£¨first-in-class£©¾²ÂöÕòÍ´Ò©¡£¡£¡£¡£¡£¡£oliceridineÊÇÊ׸öGÂѰ×Ñ¡ÔñÐÔ¼¤¶¯¼Á£¬£¬ £¬£¬£¬£¬£¬Óë¾²Âö×¢ÉäÂð·ÈÏà±È£¬£¬ £¬£¬£¬£¬£¬ÕòʹЧ¹û¸üºÃ¡£¡£¡£¡£¡£¡£oliceridineÒԦ̰¢Æ¬ÊÜÌåΪ°Ðµã£¬£¬ £¬£¬£¬£¬£¬Í¨¹ýÒ»ÖÖÓÅ»¯×÷ÓûúÖÆ£¨MOA£©£¬£¬ £¬£¬£¬£¬£¬ÓÅÏȼÓÈëÈÏÕæÁÆÐ§µÄÐźÅͨ·£¬£¬ £¬£¬£¬£¬£¬ïÔÌ­ÒýÆð²»Á¼·´Ó¦µÄÐźÅͨ·µÄ¼¤»î¡£¡£¡£¡£¡£¡£



27£¬£¬ £¬£¬£¬£¬£¬ Evrysdi(risdiplam)

risdiplamÊÇÖÎÁÆËùÓÐ3ÖÖÀàÐÍSMAµÄÊ׸ö¿Ú·þÒ©Îï¡£¡£¡£¡£¡£¡£


28£¬£¬ £¬£¬£¬£¬£¬Winlevi(clascoterone)

Clascoterone£¨ÓÖ³ÆCB-03-01£©ÊÇÒ»ÖÖ¾Ö²¿ÐÛ¼¤ËØÊÜÌ壨AR£©ÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬¸ÃÐµĻ¯Ñ§ÊµÌåÕýÔÚ¿ª·¢ÖÎÁÆðî´¯£¨Ôݶ¨Æ·ÅÆÃûΪWinlevi£©ºÍÄÐÅ®ÐÔÍÑ·¢£¨Ôݶ¨Æ·ÅÆÃûBreezula£©¡£¡£¡£¡£¡£¡£Æ¾Ö¤ÃÀ¹úFDAÉó²éÆä1%Ũ¶ÈÖÎÁÆðî´¯ÒÔ¼°ºóÆÚ¿ª·¢Æä¸ßŨ¶ÈÈÜÒºÖÎÁÆÄÐÐÔÐÛ¼¤ËØÐÛÐÔÍÑ·¢µÄЧ¹û£¬£¬ £¬£¬£¬£¬£¬Æä±»ÒÔΪÊÇÒ»ÖÖ¡°first-in-class¡±Ò©Îï¡£¡£¡£¡£¡£¡£ÖµµÃÒ»ÌáµÄÊÇ£¬£¬ £¬£¬£¬£¬£¬ÕâÊǽü40ÄêÀ´Õë¶Ôðî´¯ÖÎÁƵÄÊ׸öлúÖÆÒ©Îï¡£¡£¡£¡£¡£¡£

29£¬£¬ £¬£¬£¬£¬£¬Detectnet£¨Cu 64 DOTATATE£©·ÅÉäÐÔÕï¶ÏÊÔ¼Á Í­64ÑÎËáÑÎ

DetectnetÊÇÊ׿Cu 64·ÅÉäÐÔÍ¬Î»ËØÓëÉú³¤ÒÖËØÀàËÆÎïDOTATATEżÁªµÄÕï¶ÏÊÔ¼Á¡£¡£¡£¡£¡£¡£



30£¬£¬ £¬£¬£¬£¬£¬Pralsetinib ÆÕÀ×Î÷ÌæÄá

Pralsetinib (Blu-667) ÊÇÐÂÒ»´úµÄ£¬£¬ £¬£¬£¬£¬£¬¸ßЧµÄ£¬£¬ £¬£¬£¬£¬£¬Ñ¡ÔñÐÔRETÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬¹ØÓÚWT RET£¬£¬ £¬£¬£¬£¬£¬RETÍ»±äÌåV804L£¬£¬ £¬£¬£¬£¬£¬V804M£¬£¬ £¬£¬£¬£¬£¬M918TºÍCCDC6-RETµÄIC50Ϊ0.3-0.4 nM¡£¡£¡£¡£¡£¡£



31£¬£¬ £¬£¬£¬£¬£¬ÈðµÂÎ÷Τ£¨Remdesivir£©

2020Äê10ÔÂ22ÈÕ£¬£¬ £¬£¬£¬£¬£¬ÃÀ¹úʳÎïÒ©Æ·¹ÜÀí¾Ö£¨FDA£©Åú×¼Á˼ªÏéµÂ¿ÆÑ§µÄ¿¹²¡¶¾Ò©ÎïÈðµÂÎ÷ΤÓÃÓÚÖÎÁÆÐ¹ÚסԺ»¼Õߣ¬£¬ £¬£¬£¬£¬£¬³ÉΪÃÀ¹úÊ׸öÕýʽ»ñÅúµÄйÚÖÎÁÆÒ©Îï¡£¡£¡£¡£¡£¡£



32£¬£¬ £¬£¬£¬£¬£¬Lonafarnib (Synonyms: Sch66336)

Lonafarnib ÊÇÒ»ÖÖ¿Ú·þÓÐÓõķ¨Äá»ùÂѰ××ªÒÆÃ¸ (FPTase) ÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬×÷ÓÃÓÚ H-ras£¬£¬ £¬£¬£¬£¬£¬K-ras ºÍ N-ras£¬£¬ £¬£¬£¬£¬£¬IC50 »®·ÖΪ 1.9 nM£¬£¬ £¬£¬£¬£¬£¬5.2 nM ºÍ 2.8 nM¡£¡£¡£¡£¡£¡£Lonafarnib ¾ßÓп¹¸ÎÑ×Èý½ÇÖÞ²¡¶¾ (HDV) µÄ»îÐÔ¡£¡£¡£¡£¡£¡£



33£¬£¬ £¬£¬£¬£¬£¬ Imcivree(Setmelanotide)

setmelanotideÊÇÒ»¿îÊ×´´¡¢¹ÑëÄÀàMC4R¼¤¶¯¼Á£¬£¬ £¬£¬£¬£¬£¬¿ª·¢ÓÃÓÚÖÎÁÆÓÐÊý·ÊÅÖÒÅ´«ÐÔ¼²²¡¡£¡£¡£¡£¡£¡£

34£¬£¬ £¬£¬£¬£¬£¬Gallium 68 PSMA-11


35£¬£¬ £¬£¬£¬£¬£¬Orladeyo£¨Berotralstat£©±´ÂÞ˾Ëû

rladeyo£¨Berotralstat£©±´ÂÞ˾Ëû  ÊÇÒ»ÖÖÐÂÐÍ¡¢¿Ú·þ¡¢ÖðÈÕ1´Î¡¢Ç¿Ð§¡¢Ñ¡ÔñÐÔÈËѪ½¬¼¤ëÄÊÍ·ÅøÒÖÖÆ¼Á£¬£¬ £¬£¬£¬£¬£¬Í¨¹ýÒÖÖÆ¼¤ëÄÊÍ·ÅøÀ´×èÖ¹»º¼¤ëĵÄÌìÉú´Ó¶øÔ¤·ÀË®Ö×±¬·¢¡£¡£¡£¡£¡£¡£Orladeyo £¨berotralstat£©ÓÃÓÚÔ¤·À12Ëê¼°ÒÔÉ϶ùͯºÍ³ÉÈËÒÅ´«ÐÔѪ¹ÜÐÔË®Ö×£¨HAE£©±¬·¢£¬£¬ £¬£¬£¬£¬£¬OrladeyoÊÇÊ׸öÔ¤·ÀHAE±¬·¢µÄ¿Ú·þ·ÇçÞÌåÒ©Îï¡£¡£¡£¡£¡£¡£



36£¬£¬ £¬£¬£¬£¬£¬Tirbanibulin (Synonyms: KX2-391; KX-01)





37£¬£¬ £¬£¬£¬£¬£¬Relugolix Èð¬¸êÀû

Relugolix£¬£¬ £¬£¬£¬£¬£¬Ò²³ÆÎªTAK-385£¬£¬ £¬£¬£¬£¬£¬ÊÇÒ»ÖÖ¿Ú·þ»îÐԵĻÆÌå¼¤ËØÊͷż¤ËØ£¨LH-RH£©ÊÜÌåÞ׿¹¼Á£¬£¬ £¬£¬£¬£¬£¬IC50Ϊ0.12 nM¡£¡£¡£¡£¡£¡£





38, Gemtesa£¨vibegron£©

vibegron¿ÉÖÎÁưòë×Ì«¹ýÔ˶¯Ö¢µ¼ÖÂµÄÆÈÇÐÐÔÄòʧ½û£¬£¬ £¬£¬£¬£¬£¬Äò¼±ºÍÄòƵµÈÖ¢×´¡£¡£¡£¡£¡£¡£




±¾ÎIJ¿·ÖÄÚÈÝÔ´×ÔÍøÂç

---------------------------------------------------------------------

Óɴ˿ɼû£¬£¬ £¬£¬£¬£¬£¬Ð¡·Ö×ÓÒ©ÎïÑз¢ÒѳÉΪÁ˵±ÏÂÈ«ÇòÒ©ÎïÑз¢µÄÖ÷Á÷Ö®Ò»£¬£¬ £¬£¬£¬£¬£¬¶ø7790±Ø·¢¼¯ÍÅÒ½Ò©ÔÚС·Ö×ÓÒ©ÎïÑз¢ÁìÓòÒàÊÇ·¢Á¦ÔÚ¼´¡£¡£¡£¡£¡£¡£ÔÚÉî¸Û¿Æ¼¼ºÏ×÷ÏÈÐÐÊ÷Ä£ÇøÒªµØÉîÛÚ¸£Ì£¬ £¬£¬£¬£¬£¬7790±Ø·¢¼¯ÍÅÒ½Ò©½¨ÉèÈ«×Ê×Ó¹«Ë¾²©ÈðÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾£¬£¬ £¬£¬£¬£¬£¬È«Á¦¸³ÄÜ´óÍåÇøÓµÓиüÍêÉÆµÄС·Ö×ÓÒ»Ì廯ÐÂÒ©Ñз¢·þÎñƽ̨ºÍÄÜÁ¦¡£¡£¡£¡£¡£¡£

7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
  • µç»°£º020-38473208
  • µØÖ·£ºÁÙ´²ÖÐÐÄ£º¹ãÖÝÊÐÌìºÓÇø»ª¹Û·1933 ºÅÍò¿ÆÔƹ㳡A¶°7Â¥ / ʵÑéÊÒµØÖ·£º¹ãÖÝÊÐ»ÆÆÒÇøÄÏÏèÒ»Æð62ºÅ
  • »¥ÁªÍøÒ©Æ·ÐÅÏ¢·þÎñ×ʸñÖ¤Êé
Copyright ? 7790±Ø·¢¼¯ÍÅ All Rights Reserved ÔÁICP±¸13039920ºÅ £¨ÔÁ£©¡ª·Çı»®ÐÔ¡ª2020-0084

ÔÁ¹«Íø°²±¸ 44011202001884ºÅ

Powered by vancheer
Copyright ? 7790±Ø·¢¼¯ÍÅ All Rights Reserved ÔÁICP±¸13039920ºÅ £¨ÔÁ£©¡ª·Çı»®ÐÔ¡ª2020-0084

ÔÁ¹«Íø°²±¸ 44011202001884ºÅ

Powered by vancheer
7790±Ø·¢¼¯ÍÅ(Öйú)ÓÐÏÞ¹«Ë¾-Ëѹ·°Ù¿Æ
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿